Wockhardt Ltd.
NSE: WOCKPHARMAWockhardt Ltd.: A 30-second snapshot
WOCKPHARMA trades at Rs 1,916.5, up 14.25% over 12 months and 34.49% over the trailing 3 months, sitting above both its 50-DMA (Rs 1,898.55) and 200-DMA (Rs 1,503.81) while still 20.88% below its 52-week high. The stock carries a PE of 146.97 against an ROE of 4.01%, a D/E of 42.284, and a quality score of 31, ranking 4th of 6 among tracked Pharma peers, with RSI at 55.22 in neutral territory.
P/E
147.0
Forward P/E
—
ROE
+4.0%
Debt / Equity
42.28
Profit Margin
+6.2%
Div. Yield
—
5Y ROE > 15%
0/5
5Y FCF > 0
2/5
Quality
38/100
News
8 headlines · 0 positive · 1 negative
Wockhardt Share Kyu Gir Rha Hai? | Wockhardt Q4 Results 2026 Voiture électrique (J2NUgXq3vI) - Mshale
Mshale
Wockhardt Limited Revenue Breakdown – NSE:WOCKPHARMA - TradingView
TradingView
Dr. Reddy's Laboratories slides Monday, underperforms competitors - MarketWatch
MarketWatch
Wockhardt ASM लिस्ट में शामिल? Wockhardt Share Latest News, Wockpharma. Wockhardt Pharma Share Ryan Miller (k9ZqlIEp4a) - Mshale
Mshale
Wockhardt Share Latest News | Wockhardt Share Price Target, Wockhardt Share Analysis Wockhardt Share Connor Bedard (JYnYp8aL8a) - Mshale
Mshale
Recent context
- ·Stock sits 20.88% below its 52-week high despite the recent 3-month rally of 34.49%.
- ·News coverage (8 articles, July 18-27, 2026) is neutral overall (0 positive / 7 neutral / 1 negative); one Mshale headline from July 18 is framed around the stock 'falling' (Hindi: 'Wockhardt Share Kyu Gir Rha Hai?').
- ·Pharma-sector news flow in the same window included Dr. Reddy's Laboratories noted as underperforming peers (MarketWatch, July 27).
Strengths
- +Trades above both the 50-DMA and 200-DMA, up 14.25% over 12 months and 34.49% over the trailing 3 months.
- +5-year revenue growth of 36.4%.
- +Debt trend is classified as flat rather than rising, per the tracked persistence data.
- +News flow over the 8-article sample is dominated by neutral coverage (7 of 8), with only 1 negative and 0 positive items - no concentrated negative catalyst.
Weaknesses
- −Debt-to-equity of 42.284 is far above the >4 leverage caution level, alongside an ROE of just 4.01%.
- −ROE exceeded 15% in zero of the tracked years and free cash flow was positive in only 2 of those years, with a consistency score of 23.
- −Trailing PE of 146.97 is elevated relative to the 4.01% ROE and 6.15% net margin.
- −Ranks last (6th of 6) on PE and 5th of 6 on ROE among Pharma peers, with a quality score of 31 (4th of 6).
Open questions
- ?Does the 3-month price rally of 34.49% reflect an operational catalyst, or is it a re-rating disconnected from the 4.01% ROE and consistency score of 23 in the fundamentals?
- ?What is driving the D/E of 42.284, and how does it compare with WOCKPHARMA's own leverage trend beyond the 'flat' classification?
- ?How does a trailing PE of 146.97 relate to the company's growth trajectory and 6.15% net margin relative to Pharma peers trading at PE multiples of 28.7 to 75.1?
- ?What would need to change in free cash flow generation, positive in only 2 of the tracked years, for capital-efficiency metrics to become more consistent?
Peer comparison: Pharma
Ranks 4 of 6 on quality| Symbol | Name | P/E | ROE | Quality |
|---|---|---|---|---|
| WOCKPHARMA | Wockhardt Ltd.You're viewing | 147.0 | +4.0% | 31 |
| Industry avg | across 5 peers | 49.4 | +14.8% | 34 |
| SUNPHARMA | Sun Pharmaceutical Industries Ltd. | 41.6 | +14.7% | 56 |
| APOLLOHOSP | Apollo Hospitals Enterprise Ltd. | 66.0 | +21.5% | 44 |
| MAXHEALTH | Max Healthcare Institute Ltd. | 75.1 | +14.3% | 37 |
| CIPLA | Cipla Ltd. | 35.3 | — | 28 |
| DRREDDY | Dr. Reddy's Laboratories Ltd. | 28.7 | +8.8% | 4 |
Technical state
Current price
₹1,916.50
SMA 50
₹1,898.55
SMA 200
₹1,503.81
RSI (14)
55.2 (neutral)
From 52w high
-20.9%
1Y return
+14.3%
3M return
+34.5%
50-DMA
Above
200-DMA
Above
Algorithmic support levels
Algorithmic resistance levels
Risk flags
- highDebt-to-equity of 42.284 sits far above the >4 caution level used for non-bank leverage; ROE of 4.01% and a consistency score of 23 indicate the balance sheet is carrying above-threshold leverage without matching returns on equity.
- highROE exceeded 15% in zero of the tracked years and free cash flow was positive in only 2 of those years. The trailing PE of 146.97 sits well above what a 4.01% ROE and 6.15% net margin would typically support.
- mediumWithin the 6-stock Pharma peer set, WOCKPHARMA ranks last (6th) on PE, 5th on ROE, and 4th on quality score (31 of 100) - bottom-of-group on valuation and below-median on composite quality versus APOLLOHOSP, CIPLA, DRREDDY, MAXHEALTH and SUNPHARMA.
- lowAnalyst rating and coverage count are both unavailable; the news sample is limited to 8 articles (0 positive / 7 neutral / 1 negative), a small base for sentiment inference.
Cross-section contradictions
- Price trades above both the 50-DMA (Rs 1,898.55) and 200-DMA (Rs 1,503.81), up 34.49% over the trailing 3 months and 14.25% over 12 months, yet ROE is 4.01%, the consistency score is 23, and D/E is 42.284 - price momentum diverges from reported capital-efficiency and leverage metrics.
- News sentiment across the 8-article sample is neutral-to-mixed (0 positive / 7 neutral / 1 negative, including a headline framed around the stock 'falling'), even as the stock is up 34.49% over the trailing 3 months and sits only 20.88% below its 52-week high - recent news flow does not reflect the price strength.
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 11 Aug 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 30 Jul 2026 · rotates through NIFTY 500 every ~5 days